ExodusPoint Capital Management LP Sells 15,109 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

ExodusPoint Capital Management LP lessened its stake in ADMA Biologics, Inc. (NASDAQ:ADMA – Get Rating) by 22.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,489 shares of the biotechnology company’s stock after selling 15,109 shares during the period. ExodusPoint Capital Management LP’s holdings in ADMA Biologics were worth $125,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of ADMA. JPMorgan Chase & Co. raised its position in ADMA Biologics by 360.0% during the 1st quarter. JPMorgan Chase & Co. now owns 79,106 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 61,909 shares during the last quarter. Raymond James & Associates raised its position in ADMA Biologics by 24.0% during the 1st quarter. Raymond James & Associates now owns 199,984 shares of the biotechnology company’s stock valued at $366,000 after purchasing an additional 38,715 shares during the last quarter. Bank of New York Mellon Corp raised its position in ADMA Biologics by 79.6% during the 1st quarter. Bank of New York Mellon Corp now owns 83,401 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 36,967 shares during the last quarter. Bank of Montreal Can bought a new position in ADMA Biologics during the 1st quarter valued at approximately $1,665,000. Finally, BlackRock Inc. raised its position in ADMA Biologics by 0.8% during the 1st quarter. BlackRock Inc. now owns 4,107,382 shares of the biotechnology company’s stock valued at $7,517,000 after purchasing an additional 31,791 shares during the last quarter. Institutional investors own 71.17% of the company’s stock.

ADMA Biologics Stock Down 1.2 %

Shares of NASDAQ:ADMA opened at $3.42 on Friday. ADMA Biologics, Inc. has a 52-week low of $1.43 and a 52-week high of $3.98. The firm has a market capitalization of $672.99 million, a P/E ratio of -9.24 and a beta of 0.87. The stock has a 50 day moving average price of $3.59 and a 200-day moving average price of $3.14. The company has a debt-to-equity ratio of 1.51, a quick ratio of 1.38 and a current ratio of 5.04.

Analyst Ratings Changes

A number of research analysts have commented on ADMA shares. Mizuho upped their price target on ADMA Biologics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, November 10th. HC Wainwright reaffirmed a “buy” rating and set a $4.50 price target on shares of ADMA Biologics in a research report on Wednesday, February 8th.

Insider Transactions at ADMA Biologics

In other news, CEO Adam S. Grossman bought 14,983 shares of the firm’s stock in a transaction dated Friday, December 9th. The stock was purchased at an average price of $2.86 per share, with a total value of $42,851.38. Following the transaction, the chief executive officer now owns 2,203,708 shares of the company’s stock, valued at $6,302,604.88. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

About ADMA Biologics

(Get Rating)

ADMA Biologics, Inc operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations.